Return to QS102 Overview

Bipolar disorder, psychosis and schizophrenia in children and young people [QS102]

Measuring the use of this guidance

Statement: 6

Children and young people with bipolar disorder, psychosis or schizophrenia prescribed antipsychotic medication have their treatment monitored for side effects.

Quality standard measure: Proportion of children and young people with bipolar disorder, psychosis or schizophrenia prescribed antipsychotic medication for more than a year with a record of side‑effect monitoring within the last 6 months.
What was measured: Proportion of children and adolescents prescribed antipsychotics who have bi-annual recording of height, weight, blood pressure, pulse rate and review of side effects.
Data collection end: March 2017
100%
Area covered: UK
Source: Gnanavel Sundar, and Hussain Sharafat (2018) Audit of physical health monitoring in children and adolescents receiving antipsychotics in neurodevelopmental clinics in Northumberland. World journal of psychiatry 8(1), 27-32

Quality standard measure: Proportion of children and young people with bipolar disorder, psychosis or schizophrenia prescribed antipsychotic medication for more than a year with a record of side‑effect monitoring within the last 6 months.
What was measured: Proportion of children and adolescents prescribed antipsychotics who have annual monitoring for blood tests including liver function, renal function full blood count as well as bi-annual monitoring of serum prolactin and serum lipid profile.
Data collection end: March 2017
56%
Area covered: UK
Source: Gnanavel Sundar, and Hussain Sharafat (2018) Audit of physical health monitoring in children and adolescents receiving antipsychotics in neurodevelopmental clinics in Northumberland. World journal of psychiatry 8(1), 27-32



 Return to QS102 Overview